Uwe Reuter, MD, PhD, MBA, Charité – University Medicine Berlin, Berlin, Germany, discusses the 2-year interim results of the LIBERTY trial (NCT03096834). This study evaluated the efficacy and safety of erenumab in episodic migraine patients who have unsuccessfully failed other preventive migraine treatments. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).